Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0010200 (cough)
 23,843 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Pulmonary sarcoidosis is a disease in which the pathological processes are distributed along lymphatic pathways, particularly those around the bronchovascular bundles. Delivery of disease-modulating drugs by the inhaled route is therefore an attractive option. The aim of this study was to determine the efficacy of inhaled fluticasone propionate 2 mg x day(-1) in adults with stable pulmonary sarcoidosis. Forty-four adult patients (22 from each centre) were enrolled from outpatient clinics in two London teaching hospitals in a two centre, double-blind, randomized, placebo-controlled trial. Primary end points were home recordings of peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC). Secondary end points were symptom scores, use of rescue bronchodilator medication, and clinic values for PEFR, FEV1, FVC, forced mid-expiratory flow (FEF25-75%), diffusion capacity of the lung for carbon monoxide (DL,CO), and total lung capacity (TLC). Symptom scores of cough, breathlessness and wheeze were lower in the active treatment group, but this did not reach statistical significance, and a general health perception assessment (Short Form (SF)-36) showed a difference between active and placebo treatment. No significant differences were found between the two groups in any physiological outcome measure. No new adverse reactions were detected. The results of this pilot study do not show an objective benefit of inhaled fluticasone propionate in pulmonary sarcoidosis where the disease is stable and is controlled without the use of inhaled corticosteroids.
 ...
PMID:Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. 1044 10

Pulmonary sarcoidosis is an idiopathic granulomatosis with a clinical picture involving dyspnea, coughing, chest pain and characteristic radiologic changes. A review of English and Spanish language publications (PubMed 1990 through 2002) suggests that our report of a case of pulmonary sarcoidosis associated with primary antiphospholipid syndrome is the first one in the literature for this period. The patient was a 35-year-old man with venous thrombosis who later developed pulmonary sarcoidosis. The clinical course was not favorable in spite of good prognostic factors. We conclude that the association of these two clinical conditions is rare and that the presence of antiphospholipid syndrome may lead to greater morbidity and mortality.
 ...
PMID:[Pulmonary sarcoidosis and antiphospholipid syndrome]. 1271 62

Sarcoidosis has a wide varying presentation. Pulmonary sarcoidosis typically presents with bilateral hilar adenopathy and reticulonodular opacities. Very rarely it can present as a single solitary mass. Here we present a case of a 39 year old African-American male who presented with cough and pleuritic chest pain. Initial imaging revealed a right lower lobe airspace opacity, concerning for pneumonia. Despite treatment with antibiotics, symptoms and radiological findings persisted. A PET scan revealed a FDG positive right lower lobe pulmonary mass. Biopsy of the mass and lymph nodes revealed non-caseating granulomas suggestive of sarcoidosis. This case showcases a rare presentation of pulmonary nodular sarcoidosis.
 ...
PMID:Sarcoidosis presenting as a solitary pulmonary mass. 3310 99